Testimony closes in liability phase of Musk vs. Altman trial

The trial over Elon Musk’s claims against OpenAI, Sam Altman, Greg Brockman and Microsoft is moving into jury deliberations, with Musk seeking up to $134 billion in disgorgement plus nonmonetary remedies that could oust Altman and Brockman. Witnesses largely reinforced OpenAI’s and Microsoft’s defenses, including testimony that donations were used for OpenAI’s nonprofit mission and that Microsoft found no evidence of a forbidden for-profit agreement. The case remains important for AI governance and OpenAI’s control structure, but the immediate market impact is likely limited unless liability or remedies are found.

Analysis

The market is still underpricing how asymmetric the legal process is for Microsoft versus OpenAI. Even a weak liability showing likely matters less for MSFT’s economics than for governance optics: the real risk is a forced unwind or structural remedy that delays model commercialization, complicates capital raises, and pushes OpenAI toward a slower, more utility-like path. That is negative for OpenAI’s strategic flexibility but could be mildly positive for Microsoft if the outcome effectively entrenches its distribution and compute leverage while externalizing the governance overhang.

For TSLA, the second-order issue is not direct legal exposure but narrative contamination. Musk has made this case a referendum on his right to control frontier-AI strategy, and that can reprice investor attention around his bandwidth, board credibility, and willingness to pursue aggressive AI hiring away from Tesla. Any extended trial or unfavorable remedy keeps a lid on multiple expansion by reinforcing the “distracted founder / governance discount” that investors already apply to TSLA, particularly if the case underscores internal conflict between AI ambition and automotive execution.

The key catalyst is the judge’s remedies phase, which is much more market-relevant than the jury’s liability signal. Liability alone is a headline event; a remedy that touches ownership, control, or transaction unwind would likely trigger a second leg of downside in OpenAI-adjacent private assets and pressure listed AI infrastructure names through valuation comps. Conversely, a no-liability outcome would likely squeeze short-term litigation hedges but would not eliminate the broader overhang because the governance questions remain unresolved and could reappear in future fundraising or M&A processes.

Contrarian view: the consensus may be overestimating the probability that this becomes a binary winner-take-all event. The more likely outcome is a messy partial remedy that preserves the core business economics while adding friction, which tends to help MSFT relative to both TSLA and OpenAI’s private holders. That favors trading the spread between perceived AI enablers and AI control-risk names rather than taking a directional view on the headline trial outcome.

Key Decisions for Investors

• Maintain a modest long MSFT / short TSLA pair into the jury verdict window; the trade is less about trial outcome and more about MSFT’s lower governance beta versus TSLA’s founder-risk discount. Target a 2-4 week hold with stop-loss on any clean no-liability verdict that removes the governance overhang faster than expected.
• Buy short-dated TSLA puts or put spreads into Monday’s deliberations if implied volatility remains below event-risk norms; upside is limited by core automotive fundamentals, while downside extends if the case sustains the distraction narrative. Prefer 1-2 month tenor to capture remedies-phase headlines.
• Avoid initiating new long exposure in private AI names with complex nonprofit-for-profit structures until the remedies phase is clearer; the risk is not the verdict itself but forced restructuring that can reset valuation marks 10-20% lower in follow-on rounds.
• If MSFT sells off on a liability headline, use weakness to add selectively; a negative headline could be a better entry because the downside to Microsoft is primarily legal friction, while the upside from entrenched distribution and compute leverage remains intact over 6-12 months.
• For event-driven accounts, consider a small options hedge on AI infrastructure beneficiaries versus governance-sensitive names: long a basket of compute/infra leaders, short a basket of founder-controlled AI platform names. The relative trade should outperform if the court chooses a partial-remedy path.